Pacira | PCRX

Pacira Pharmaceuticals traded at $55.75 this Friday September 9th, increasing $0.12 or 0.22 percent since the previous trading session. Looking back, over the last four weeks, Pacira gained 2.55 percent. Over the last 12 months, its price rose by 0.63 percent. Looking ahead, we forecast Pacira Pharmaceuticals to be priced at 54.13 by the end of this quarter and at 49.56 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
55.75
Daily Change
0.22%
Yearly
0.63%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Astellas Pharma 2,014.00 14.50 0.73% 5.89%
AmerisourceBergen 147.27 -0.27 -0.18% 19.92%
AcelRx Pharmaceuticals 0.28 -0.01 -2.11% -72.65%
Aerie Pharmaceuticals 15.12 -0.01 -0.07% -9.08%
Bristol-Myers Squibb 70.16 0.78 1.12% 11.14%
Cara Therapeutics 10.96 0.07 0.64% -28.23%
Coherus Biosciences 10.58 0.06 0.57% -31.25%
Depomed 2.74 0.04 1.30% 177.24%
Endo International 0.10 -0.01 -5.20% -96.28%
Heron Therapeutics 5.06 0.29 6.08% -56.57%
Horizon Pharma 66.09 4.06 6.55% -38.66%
Ironwood Pharmaceuticals 11.00 0.03 0.27% -9.84%
Jazz Pharmaceuticals 152.66 1.11 0.73% 13.41%
J&J 165.71 0.32 0.19% -0.75%
Lannett 0.48 0.01 2.91% -85.03%
Ligand Pharmaceuticals 96.10 0.33 0.34% -29.77%
Nektar Therapeutics 3.74 -0.02 -0.53% -76.55%
Omeros 5.35 -0.09 -1.65% -65.77%
Pacira 55.75 0.12 0.22% 0.63%
Pfizer 47.84 0.76 1.61% 4.94%
Perrigo 39.15 0.55 1.42% -10.39%
Revance Therapeutics 28.47 3.17 12.53% 4.98%
Supernus Pharmaceuticals 34.65 0.10 0.29% 30.31%
Teva Pharmaceutical Industries Ltd 3,040.00 41.00 1.37% 1.10%
Xeris Pharmaceuticals Inc 1.82 0.03 1.68% -31.84%
Xoma 17.00 -0.02 -0.12% -34.72%
Zoetis 164.31 5.82 3.67% -20.62%

Indexes Price Day Year
USND 12112 250.18 2.11% -19.87%
US2000 1883 35.94 1.95% -15.47%

Pacira
Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its other product candidate, the iovera system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature only to targeted nerves. The iovera system is complementary to EXPAREL as a non-opioid therapy that alleviates pain using a non-pharmacological nerve block to disrupt pain signals being transmitted to the brain from the site of injury or surgery.